Advances in High-Resolution MS and Hepatocyte Models Solve A Long-Standing Metabolism Challenge: The Loratadine Story

References

• US FDA . United States FDA 2004 PDUFA performance report. Performance Reports (2004). www.fda.gov/AboutFDA/ReportsManualsForms/Reports/UserFeeReports/PerformanceReports/ucm2007449.htm.
   Google Scholar
• Ramanathan R , AlvarezN, SuADet al. Metabolism and excretion of loratadine in male and female mice, rats and monkeys. Xenobiotica35 (2), 155–189 (2005).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , ReydermanL, KulmatyckiKet al. Disposition of loratadine in healthy volunteers. Xenobiotica37 (7), 753–769 (2007).
   PubMed Web of Science ®Google Scholar
• Ghosal A , GuptaS, RamanathanRet al. Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab. Lett. 3 (3), 162–170 (2009).
   PubMedGoogle Scholar
• Ghosal A , YuanY, HapangamaNet al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of 3-hydroxydesloratadine. Biopharm. Drug Dispos. 25 (6), 243–252 (2004).
   PubMed Web of Science ®Google Scholar
• Kazmi F , YerinoP, BarbaraJE, ParkinsonA. Further characterization of the metabolism of desloratadine and its cytochrome P450 and UDP-glucuronosyltransferase inhibition potential: identification of desloratadine as a relatively selective UGT2B10 inhibitor. Drug Metab. Dispos. 43 (9), 1294–1302 (2015).
   PubMed Web of Science ®Google Scholar
• Kazmi F , BarbaraJE, YerinoP, ParkinsonA. A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 43 (4), 523–533 (2015).
   PubMed Web of Science ®Google Scholar
• Foti RS , FisherMB. Impact of incubation conditions on bufuralol human clearance predictions: enzyme lability and nonspecific binding. Drug Metab. Dispos. 32 (3), 295–304 (2004).
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ , CastellJV, DonatoMT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin. Drug Metab. Toxicol. 4 (7), 837–854 (2008).
   PubMed Web of Science ®Google Scholar
• Dalvie D , ObachRS, KangPet al. Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem. Res. Toxicol. 22 (2), 357–368 (2009).
   PubMed Web of Science ®Google Scholar
• Smith CM , NolanCK, EdwardsMAet al. A comprehensive evaluation of metabolic activity and intrinsic clearance in suspensions and monolayer cultures of cryopreserved primary human hepatocytes. J. Pharm. Sci. 101 (10), 3989–4002 (2012).
   PubMed Web of Science ®Google Scholar
• Khetani SR , BhatiaSN. Microscale culture of human liver cells for drug development. Nat. Biotechnol. 26 (1), 120–126 (2008).
   PubMed Web of Science ®Google Scholar
• Wang WW , KhetaniSR, KrzyzewskiS, DuignanDB, ObachRS. Assessment of a micropatterned hepatocyte coculture system to generate major human excretory and circulating drug metabolites. Drug Metab. Dispos. 38 (10), 1900–1905 (2010).
   PubMed Web of Science ®Google Scholar
• Chan TS , YuH, MooreA, KhetaniSR, TweedieD. Meeting the challenge of predicting hepatic clearance of compounds slowly metabolized by cytochrome P450 using a novel hepatocyte model, HepatoPac. Drug Metab. Dispos. 41 (12), 2024–2032 (2013).
   PubMed Web of Science ®Google Scholar
• Ballard TE , WangS, CoxLMet al. Application of a micropatterned cocultured hepatocyte system to predict preclinical and human-specific drug metabolism. Drug Metab. Dispos. 44 (2), 172–179 (2016).
   PubMed Web of Science ®Google Scholar
• Hopfgartner G , TonoliD, VaresioE. High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices. Anal. Bioanal. Chem. 402 (8), 2587–2596 (2012).
   PubMed Web of Science ®Google Scholar
• Andrews GL , SimonsBL, YoungJB, HawkridgeAM, MuddimanDC. Performance characteristics of a new hybrid quadrupole time-of-flight tandem mass spectrometer (TripleTOF 5600). Anal. Chem. 83 (13), 5442–5446 (2011).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , RamagiriS, Aratyn-SchausYet al. Advances in HRMS and in vitro systems provide an option to detect and characterize human disproportionate metabolites of loratadine/desloratadine Presented at : The 63rd ASMS Conference on Mass Spectrometry. MO, USA, 31 May–4 June 2015.
   Google Scholar
• Sidoli S , LinS, XiongLet al. Sequential Window Acquisition of all Theoretical Mass Spectra (SWATH) analysis for characterization and quantification of histone post-translational modifications. Mol. Cell. Proteomics14 (9), 2420–2428 (2015).
   PubMed Web of Science ®Google Scholar
• Wohlfarth A , CastanetoMS, ZhuMet al. Pentylindole/pentylindazole synthetic cannabinoids and their 5-fluoro analogs produce different primary metabolites: metabolite profiling for AB-PINACA and 5F-AB-PINACA. AAPS J. 17 (3), 660–677 (2015).
   PubMed Web of Science ®Google Scholar
• Zelesky V , SchneiderR, JaniszewskiJ, ZamoraI, FergusonJ, TroutmanM. Software automation tools for increased throughput metabolic soft-spot identification in early drug discovery. Bioanalysis5 (10), 1165–1179 (2013).
   PubMed Web of Science ®Google Scholar
• Yumibe N , HuieK, ChenKJ, SnowM, ClementRP, CayenMN. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem. Pharmacol. 51 (2), 165–172 (1996).
   PubMed Web of Science ®Google Scholar
• US FDA . FDA (2010) Guidance for Industry M3(R2). Nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (2010).
   Google Scholar
• Gao H , ObachRS. A simple liquid chromatography-tandem mass spectrometry method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments (metabolites in safety testing). II. Application to unstable metabolites. Drug Metab. Dispos. 40 (7), 1290–1296 (2012).
   PubMed Web of Science ®Google Scholar
• Gao H , ObachRS. Addressing MIST (metabolites in safety testing): bioanalytical approaches to address metabolite exposures in humans and animals. Curr. Drug Metab. 12 (6), 578–586 (2011).
   PubMed Web of Science ®Google Scholar
• Ramanathan R , JosephsJL, JemalM, ArnoldM, HumphreysWG. Novel MS solutions inspired by MIST. Bioanalysis2 (7), 1291–1313 (2010).
   PubMed Web of Science ®Google Scholar
• Khetani SR , BergerDR, BallingerKR, DavidsonMD, LinC, WareBR. Microengineered liver tissues for drug testing. J. Lab. Autom. 20 (3), 216–250 (2015).
   PubMedGoogle Scholar
• Davidson MD , WareBR, KhetaniSR. Stem cell-derived liver cells for drug testing and disease modeling. Discov. Med. 19 (106), 349–358 (2015).
   PubMed Web of Science ®Google Scholar
• Ware BR , BergerDR, KhetaniSR. Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol. Sci. 145 (2), 252–262 (2015).
   PubMed Web of Science ®Google Scholar
• Nguyen TV , UkairoO, KhetaniSRet al. Establishment of a hepatocyte-kupffer cell coculture model for assessment of proinflammatory cytokine effects on metabolizing enzymes and drug transporters. Drug Metab. Dispos. 43 (5), 774–785 (2015).
   PubMed Web of Science ®Google Scholar